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CCL19 reduces tumour burden in a model of advanced lung
cancer
S Hillinger*,1, S-C Yang2, RK Batra2, RM Strieter2, W Weder1, SM Dubinett2 and S Sharma2
1Thoracic Surgery, University Hospital Zu¨rich, Zu¨rich, Switzerland; 2Department of Medicine, David Geffen School of Medicine, University of California Los
Angeles, Los Angeles, CA, USA
Epstein–Barr virus-induced molecule 1 ligand chemokine (CCL19) is a CC chemokine that chemoattracts both dendritic cells (DC)
and T lymphocytes. We evaluated the antitumour efficacy of CCL19 in a murine model of spontaneous bronchoalveolar cell
carcinoma. These transgenic mice (CC-10 TAg) express the SV40 large T antigen under the Clara Cell promoter, develop bilateral,
multifocal, pulmonary carcinomas and die at 4 months owing to progressive pulmonary tumour burden. To mimic therapy in late-
stage disease, 3-month-old transgenic mice were treated with recombinant CCL19 (0.5mg dose1) by intranodal (axillary lymph node
region) injection three times per week for 4 weeks. CCL19 treatment led to a marked reduction in tumour burden with extensive
mononuclear infiltration of the tumours compared to diluent treated controls. Flow cytometric analyses showed significant increases
in CD4 and CD8T cell subsets as well as DC in the lungs of CCL19-treated mice. Lung tissue cytokine profiles showed a shift towards
immune stimulatory molecules with a decrease in the immunosuppressive cytokine TGF-b. Our findings show that CCL19 may serve
as a potential immune stimulator and provide a strong rationale for the evaluation of CCL19 in cancer immunotherapy.
British Journal of Cancer (2006) 94, 1029–1034. doi:10.1038/sj.bjc.6603061 www.bjcancer.com
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Lung cancer is the leading cause of cancer death in the United
States and in the world (Jemal et al, 2004). With the existing
therapeutic efforts, patients with lung cancer still have a poor
prognosis and less than 15% live 5 years. This dismal statistic has
changed minimally in the last 20 years and, therefore, new
therapeutic strategies are clearly needed.
Effective antitumour responses require both antigen-presenting
cells (APC) and lymphocyte effectors (Huang et al, 1994).
Although lung cancers express tumour antigens (Yu et al, 1997),
they are ineffective as APCs (Qin et al, 1997) because tumour cells
often have limited expression of MHC Ags and lack co-stimulatory
molecules (Restifo et al, 1993). In addition, tumour cells produce
immune inhibitory factors that promote escape from immune
surveillance (Huang et al, 1998; Sharma et al, 1999). Consequently,
effective anticancer immunity may be achieved by recruiting
professional host APC for tumour Ag presentation to promote
specific T-cell activation (Miller et al, 2000).
Chemokines are a group of homologous, yet functionally
divergent proteins that directly mediate leucocyte CXCL9/MIGra-
tion and activation and play a role in regulating angiogenesis
(Baggiolini et al, 1997). Epstein– Barr virus-induced molecule 1
ligand chemokine (ELC/CCL19) is produced by a subset of
dendritic cells (DC), and possibly by other non-lymphoid cells,
in T-cell areas of lymphoid tissue (Ngo et al, 1998). CCL19 ability
to chemoattract T cells (Kim et al, 1998a, b, 1999; Ngo et al, 1998),
B cells (Kim et al, 1998a, 1999), DC (Dieu et al, 1998), macrophage
progenitor cells (Kim et al, 1998c) and NK cells (Kim et al, 1999) is
mediated through the specific G protein-coupled seven trans-
membrane domain chemokine receptor CCR7. Based on the
capacity of CCL19 to facilitate co-localisation of both DC and T
cells, we and others are evaluating the capacity of CCL19 to reverse
tumour-mediated immune suppression and orchestrate effective
cell-mediated immune responses. In recent studies, murine breast
tumour cells transduced by a retroviral vector expressing CCL19
were rejected in vivo by a mechanism that involves both CD4þ
and NK cells (Braun et al, 2000). Utilising subcutaneous murine
lung cancer models, we have previously shown that CCL19
promotes IFN-g-dependent antitumour responses (Hillinger et al,
2003).
In this study, utilising a transgenic murine model of sponta-
neous lung cancer that more closely resembles human lung cancer,
we demonstrate that CCL19 mediates potent antitumour responses
in vivo leading to significant tumour reduction.
MATERIALS AND METHODS
CC-10 TAg mice
The transgenic CC-10 TAg mice, in which the SV40 large T antigen
is expressed under control of the murine Clara cell-specific
promoter, were used in these studies (Magdaleno et al, 1997). Mice
expressing the transgene developed diffuse bilateral bronchoalveo-
lar carcinoma in the lung. Tumours were evident bilaterally by
microscopic examination as early as 4 weeks of age. After 3 months
of age, the bronchoalveolar pattern of tumour growth coalesced to
form multiple bilateral tumour nodules. The CC-10 TAg transgenicRevised 23 February 2006; accepted 24 February 2006
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mice had an average lifespan of 4 months. Extra-thoracic
metastases were not noted. Breeding pairs for these mice were
generously provided by Francesco J DeMayo (Baylor College
of Medicine, Houston, TX, USA). Transgenic mice were bred at
the West Los Angeles Veteran Affairs vivarium and maintained
in the West Los Angeles Veterans Administration Association
for Assessment and Accreditation of Laboratory Animal Care-
accredited Animal Research Facility. Before each experiment
utilising the CC-10 TAg transgenic mice, presence of the transgene
was confirmed by PCR of mouse-tail biopsies as described
previously (Sharma et al, 2001). All of the experiments used
pathogen-free CC-10 TAg transgenic mice at 3 months of age. All
procedures were carried out in accordance with the Guidelines for
the Welfare of Animals in Experimental Neoplasia (UKCCCR,
1998).
The CCL19 therapeutic model in CC-10 TAg mice
CC-10 TAg transgenic mice were injected in the axillary lymph
node region with murine recombinant CCL19 (0.5 mg injection1;
Pepro Tech, Rocky Hill, NJ, USA) or normal saline diluent, which
contained equivalent amounts of murine serum albumin (Sigma
Chemical Co., St Louis, MO, USA) as an irrelevant protein for
control injections. Starting at 12 weeks of age, CCL19 or control
injections were administered three times per week for 4 weeks. At
the age of 4 months, mice were killed, and lungs were isolated for
quantification of tumour surface area. Tumour burden was
assessed by microscopic examination of H&E-stained sections
with a calibrated graticule (a 1-cm2 grid subdivided into 100
1-mm2 squares). A grid square with tumour occupying 450% of
its area was scored as positive, and the total number of positive
squares was determined as described previously (Sharma et al,
1999). Ten separate fields from four histological sections of the
lungs were examined under high power ( 20 objective).
Cytokine determination from tumour nodules and spleens
by ELISA
The cytokine profiles in lung tumours and spleens were
determined in both CCL19 and diluent-treated mice as described
previously (Sharma et al, 1999). The lungs were harvested and cut
into small pieces and homogenised for cytokine determinations
(Bellco, Vineland, NJ, USA). Spleens from the various treatment
groups were isolated, teased apart, RBC depleted with ddH2O, and
brought to tonicity with 1PBS. Spleen cells were cultured for
24 h and cytokines and PGE-2 determined in the culture super-
natants. The amounts of IL-10, IL-12, GM-CSF, IFN-g, TGF-b,
CXCL9/MIG, and CXCL10/IP-10 were quantified by ELISA and that
of PGE-2 by EIA. Tumour-derived cytokine and PGE-2 concentra-
tions were corrected for total protein by Bradford assay (Sigma
Chemical Co., St Louis, MO, USA) and the results expressed as
pg mg1 of total protein. For the TGF-b ELISA measurements,
samples were acidified and hence the active form of TGF-b was
measured. The sensitivities of the IL-10, GM-CSF, IFN-g, TGF-b,
IL-12, and CXCL10 ELISA were 15 pg ml1. The plates were read at
490 nm with a Molecular Devices Microplate reader (Sunnyvale,
CA, USA).
PGE2 EIA
The concentrations of PGE2 were determined using a kit from
Cayman Chemical Co. (Ann Arbor, MI, USA) according to the
manufacturer’s instructions as described previously (Huang et al,
1998). The EIA plates were read by a Molecular Devices Microplate
reader (Sunnyvale, CA, USA).
Flow cytometry
For flow cytometric experiments, two or three fluorochromes (PE,
FITC, and Tri-color; PharMingen) were used to gate on the CD3 T
lymphocytes in the percol purified leucocyte populations
from tumour nodules as described previously (Yang et al,
2004). Dendritic cells were defined as the double-stained
CD11cþDEC205þ bright populations within the purified leuco-
cyte populations from the tumour nodules. T-regulatory cells in
the purified leucocyte populations from the tumour nodules were
stained for the cell surface markers CD4 and CD25. Flow
cytometric analyses were performed on a FACScan flow cytometer
(Becton Dickinson, San Jose, CA, USA) in the University of
California, Los Angeles, Jonsson Cancer Center Flow Cytometry
Core Facility. Between 10 000 and 15 000 gated events were
collected and analysed using Cell Quest software (Becton Dick-
inson).
RESULTS
CCL19 has potent systemic antitumour responses in vivo (Figures
1 and 2); it enhances the frequency of T-cell subsets and DCs at the
tumour sites (Table 1); it promotes type 1 cytokine and
antiangiogenic chemokine release as well as a decline in the
immunosuppressive cytokine TGF-b (Figures 3 and 4).
CCL19 mediates potent antitumour responses in a murine
model of spontaneous bronchoalveolar carcinoma
We evaluated the antitumour efficacy of CCL19 in a late-stage
spontaneous bronchoalveolar cell carcinoma model. CCL19
(0.5mg injection1) or the same concentration of murine serum
albumin was injected in the axillary lymph node region beginning
2
1
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Figure 1 CCL19 mediates potent antitumour responses in a murine
model of spontaneous lung cancer. Three-month-old CC-10 TAg mice
were injected with CCL19 (0.5mg injection1) or the same concentration of
murine serum albumin in the axillary lymph node region three times a week
for 4 weeks. H&E staining of paraffin-embedded lung tumour sections from
control-treated mice evidenced large tumour masses throughout both
lungs with few mononuclear infiltrations (A and C). In contrast, CCL19-
treated mice evidenced a marked reduction in tumour burden (B and D)
with prominent mononuclear infiltrations (1, tumour; 2, mononuclear cells).
Tumour burden was quantified within the lung by microscopy of H&E-
stained paraffin-embedded sections.
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at 12 weeks of age, three times per week and continuing for 4
weeks. At 4 months when the control mice started to succumb
because of progressive lung tumour growth, mice were killed in all
of the treatment groups, and lungs were isolated and paraffin
embedded. H&E staining of paraffin-embedded lung tumour
sections from control-treated mice revealed large tumour masses
throughout both lungs with minimal lymphocytic infiltration
(Figure 1A and C). In contrast, CCL19-treated mice had
significantly smaller tumour nodules with extensive lymphocytic
infiltration (Figure 1B and D). Mice treated with CCL19 had a
marked reduction in pulmonary tumour burden (130715 mm2)
as compared with diluent-treated control mice (495740 mm2)
(Figure 2) (Po0.001).
CCL19 treatment of CC-10 TAg mice leads to enhanced DC
and T-cell infiltrates at tumour sites
To determine if the reduced tumour burden was accompanied by
increases in T-cell and DC-infiltrates following CCL19 therapy,
flow cytometric analyses was performed on percol purified
leucocyte populations of tumour nodules. Compared with the
diluent-treated control group, the CCL19-treated CC-10 TAg mice
showed significant increases in the frequency of CD4 (20%), CD8
(50%) and CD11cþDEC205þ DC (70%) and a decrease in
CD4þCD25þ Treg (20%) cells at the tumour site (Table 1).
*Po0.001 as compared to diluent-treated control.
CCL19 therapy promotes type 1 cytokines and
antiangiogenic chemokine release but a decline in the
immunosuppressive cytokine TGF-b
Tumour progression can be modified by host cytokine profiles;
hence, we measured the cytokine production from tumour sites
and spleens following therapy. Lungs and spleens were evaluated
for the presence of IFN-g, GM-CSF, IL-12, CXCL9, CXCL10, and
TGF-b by ELISA, and PGE2 by EIA. Compared to diluent-treated
controls, the treatment group receiving CCL19 had a significant
increase in type 1 cytokines (GM-CSF, IFN-g) and antiangiogenic
chemokines (CXCL9, CXCL10) and a decrease in the immuno-
suppressive cytokine TGF-b at the tumour sites. Compared with
lungs from the diluent-treated group, CC-10 TAg mice treated with
CCL19 had a significant reduction in TGF-b (1.3-fold, Po0.05).
This was coupled with an increase in GM-CSF (two-fold, Po0.01),
IFN-g (4.2-fold, Po0.01), CXCL9 (1.4-fold, Po0.01), and CXCL10
(1.7-fold, Po0.05) within the tumour microenvironment (Figure
3A and B). Moreover, a systemic effect was evident as similar
cytokine patterns were also observed in the spleens of CCL19-
treated mice. Thus, compared with the diluent-treated group,
splenocytes from CCL19-treated CC-10 TAg mice revealed an
increase in IFN-g (2.8-fold, Po0.001), CXCL9 (3.2-fold, Po0.05),
and CXCL10 (three-fold, Po0.05) (Figure 4A and B).
DISCUSSION
Host APC are critical for the cross-presentation of tumour antigens
(Huang et al, 1994). However, tumours have the capacity to limit
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Figure 2 CCL19 mediates potent antitumour responses in a murine
model of spontaneous lung cancer. There was reduced tumour burden in
CCL19-treated CC-10 mice compared with the diluent-treated control
group . *Po0.001 compared with control tumour group, n¼ 8 mice/group.
Table 1 CCL19 enhances influx of T-cell subsets and DC at the tumour
sites
Phenotype Control ELC/CCL19
CD4+ 1770.7 2170.9*
CD8+ 3872.1 5671.8*
CD4+CD25+ 1170.2 970.1*
CD11c+DEC205+ 971.0 1571.2*
DC¼ dendritic cells. Percol purified leucocytes from the digested tumour nodules
from CCL19 and diluent-treated CC-10 TAg mice were identified as lymphocytes or
DC by staining with cell surface markers. Cell surface staining or T-cell markers CD4,
CD8, CD4+CD25+ as well as the DC markers CD11c and DEC205 were evaluated
by flow cytometry; 10 000–15 000 gated events were collected and analysed using
Cell Quest software. CCL19 treatment led to an increase in the frequency of CD4+,
CD8+, CD11c+DEC205+ DC and a modest decrease in CD4+CD25+ Treg cells
compared to the diluent-treated control (*Po0.001; n¼ 8 mice per group.) These
experiments were repeated twice. Unit: percentage of leucocytes7s.e.
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Figure 3 CCL19 therapy leads to an induction of Th1 cytokines and
antiangiogenic chemokines and a decrease in TGF-b. Following axillary
lymph node region injection of CCL19, pulmonary cytokine profiles in CC-
10 TAg mice were determined and compared with those in diluent-treated
tumour-bearing control mice. Compared with lungs from diluent-treated
CC-10 tumour-bearing mice, CC-10 TAg mice treated with CCL19 had
significant increase in GM-CSF, IFN-g, CXCL9/MIG, and CXCL10/IP-10 but
a decrease in TGF-b (A and B). *Po0.01 compared with diluent-treated
CC-10 TAg mice, n¼ 6 mice per group.
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APC maturation, function, and infiltration of the tumour site
(Gabrilovich et al, 1996, 1997, 1998; Qin et al, 1997). Thus,
molecules that attract host APC and T cells could serve as potent
agents for cancer immunotherapy.
CCL19 is produced by a subset of DCs, and possibly by other
non-lymphoid cells; in T-cell areas of lymphoid tissue (Ngo et al,
1998), it strongly attracts naı¨ve T cells and DCs. Because DCs are
potent APCs that function as principal activators of T cells,
CCL19’s capacity to facilitate the colocalisation of both DC and T
cells may reverse tumour-mediated immune suppression and
orchestrate effective cell-mediated immune responses. In addition,
CCL19 is a potent inducer of T-cell proliferation and programmes
DCs for the induction of T helper (Th) 1 rather than Th2 responses
(Marsland et al, 2005). Based on these properties, we speculated
that CCL19 would be an important protein for evaluation in cancer
immunotherapy.
In most models reported previously, the antitumour efficacy of
chemokines was determined using transplantable murine or
human tumours propagated at s.c. sites. We embarked on the
current studies to determine the antitumour properties of CCL19
in a clinically relevant model of lung cancer in which bronch-
oalveolar carcinomas develop in an organ-specific manner. The
antitumour activity of CCL19 was determined in the spontaneous
model for lung cancer by injecting recombinant CCL19 into the
axillary lymph node region of the transgenic mice. In many clinical
situations, access to lymph node sites for injection may also be
more readily achievable than intratumoral administration. The
efficacy of injecting immune stimulators in the vicinity of the
lymph nodes for the treatment of cancer has been demonstrated
previously; vaccination with tumour cell– DC hybrids in the
lymph node region led to regression of human metastatic renal
cell carcinoma (Kugler et al, 2000). Our rationale for injecting
CCL19 into the lymph node region was to colocalise DC and
T cells to the lymph nodes where they can prime specific
antitumour immune responses, and our results show that this
approach works. CCL19 injected into the axillary lymph node
region evidenced potent antitumour responses, with reduced
tumour burden as compared to mice receiving diluent control
injections. The reduced tumour burden in CCL19-treated mice
was accompanied by extensive lymphocyte as well as DC
infiltrates of the tumour sites (Figure 1 and Table 1). Although
the tumours in the transgenic mice express the SV40 T antigen, we
do not think that the CCL19-mediated increase in T and DC
infiltrates into the tumour sites is in response to the viral antigen
because in order for the tumours to grow in this model, the T cells
must be tolerised to the SV 40 T antigen. In a recent study (Yang
et al, 2006), utilising the CCR7 ligand CCL21, we have shown that
cytolytic T-cell responses were enhanced to autologous CC-10
tumours but not to syngeneic control MLE-12 tumours that also
express the SV40 T antigen. This suggests that the T-cell reactivity
against tumours in this model in response to CCR7 ligand therapy
is not owing to the viral SV40 T antigen but to tumour-specific
antigens.
It is well documented that successful immunotherapy shifts
tumour-specific T-cell responses from a type 2 to a type 1 cytokine
profile (Hu et al, 1998). T helper 1 responses depend on IFN-g to
mediate a range of biological effects that facilitate anticancer
immunity. CXCL9/MIG/CXCL9 and CXCL10/IP-10/CXCL10 are
antiangiogenic CXC chemokines induced by IFN-g that chemo-
attract activated T cells expressing the CXCR3 chemokine receptor
(Loetscher et al, 1996) and are known to have potent antitumour
and properties (Brunda et al, 1993; Luster and Leder, 1993;
Arenberg et al, 1996; Sgadari et al, 1997). The tumour sites of
CCL19-treated mice revealed significant increases in IFN-g,
CXCL10/CXCL10/IP-10, CXCL9/CXCL9/MIG, and GM-CSF. The
induction of CXCL9/CXCL9/MIG and CXCL10/CXCL10/IP-10 may
be responsible in part for the tumour reduction following CCL19
administration. Hence, the tumour reductions observed in this
model may be owing to T-cell-dependent immune resposes as well
as participation by T cells secreting IFN-g in inhibiting angiogen-
esis (Tannenbaum et al, 1998). Hence, an increase in IFN-g at the
tumour site of CCL19-treated mice could explain the relative
increases in CXCL10/IP-10 and CXCL9/MIG. Both CXCL9/MIG
and CXCL10/IP-10 are chemotactic for stimulated CXCR3-
expressing T lymphocytes that could further amplify IFN-g at the
tumour site (Farber, 1997). An increase in GM-CSF in CCL19-
treated mice could enhance DC maturation and antigen presentation
(Banchereau and Steinman, 1998). Further studies are necessary to
precisely define the host cytokines that are critical to the CCL19-
mediated antitumour response. In addition, CCL19-treated tu-
mour-bearing mice showed significant reductions in TGF-b at the
tumour sites; TGF-b is an immune inhibitory cytokine that may
potently suppress Ag and presentation, antagonise CTL generation
and macrophage activation (Bellone et al, 1999). Thus, possible
benefits of a CCL19-mediated decrease in TGF-b include promo-
tion of antigen presentation and CTL generation (Bellone et al,
1999) as well as a limitation of angiogenesis (Fajardo et al, 1996;
Tsujii et al, 1998). The increase in the type 1 cytokines was not
limited to the lung but was evident systemically. CCL19 treatment
of CC-10 TAg transgenic mice led to systemic increases in type I
cytokines and antiangiogenic chemokines. Hence, splenocytes
from CCL19-treated CC-10 TAg mice had an increase in GM-CSF,
CXCL9/MIG, and CXCL10/IP-10 as compared with diluent-treated
CC-10 TAg mice.
Regulatory T cells have been documented to function as
suppressor cells, and may play a role in the progression of cancer
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Figure 4 CCL19 therapy leads to an induction of Th1 cytokines and
antiangiogenic chemokines and a decrease in TGF-b. Following axillary
lymph node region injection of CCL19, spleen cytokine profiles in CC-10
TAg mice were determined and compared with those in diluent-treated
tumour-bearing control mice. Compared with diluent-treated CC-10 TAg
mice, splenocytes from CCL19-treated CC-10 TAg mice had significant
increases in IFN-g, CXCL9/MIG, and CXCL10/IP-10. *Po0.01 compared
with diluent-treated CC-10 TAg mice, n¼ 6 mice per group.
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(Antony and Restifo, 2005). Failure of tumour immunosurveillance
or enhanced tumour growth could be owing to an increase of
regulatory T cells producing inhibitory cytokines or directly
inhibiting immunity via specific cellular interactions at the tumour
site (Antony and Restifo, 2002; Shevach, 2002). There was a modest
decrease in the frequency of CD4þCD25þ Treg population at the
tumour site following CCL19 therapy. The decrease in Treg cells
may not be physiologically relevant in terms of numbers but may
be in terms of function. Further studies are needed to define the
functional significance of the decrease in the Treg population at
the tumour site.
Taken together, the current study indicates that CCL19 injected
in the axillary lymph node region in the late-stage spontaneous
lung cancer model leads to the generation of effective antitumour
responses. The potent antitumour properties demonstrated in this
model of spontaneous bronchoalveolar carcinoma provide a strong
rationale for additional evaluation of CCL19 regulation of tumour
immunity and its use in immunotherapy for lung cancer.
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